Revalesio Company Profile
At Revalesio, we believe we can make a difference. Science can improve a life, and hope is essential to fundamentally changing it. Our aim is to provide health and healing for people by combining innovative science with a message of hope. We value optimum health and restored lives for individuals and communities around the world.
Our team is aggressively developing our therapeutic candidates by applying the highest scientific standards in conjunction with leading academic institutions, research organizations and pharmaceutical companies. We recognize the potential power of our unique technology and are committed to rigorous testing to ensure proven, safe outcomes. Scientific excellence is a must; human lives are at stake.
Optimum human health is not found in science alone. At Revalesio, we desire to restore hope to people around the world. Physical health can change lives; however, hope can transform lives.
News from Revalesio:
Revalesio's RNS60 Enhances Synaptic Function
TACOMA, Wash., Feb. 13, 2014 /PRNewswire/ — Noted neuroscientist Dr. Rodolfo Llinas and colleagues have published an article reporting that Revalesio's RNS60 improves synaptic transmission. Synapses connect nerve cells and allow communication through the release of neurotransmitters, which are essential for normal function of the nervous system and overall brain activity. In their work, Dr. […]
Revalesio Presents Update on the Development of RNS60 As A Therapeutic for Acute Heart Disease At the American Heart Association Scientific Sessions
TACOMA, Wash., Nov. 18, 2013 /PRNewswire/ — Revalesio presented an update on the cellular protective effects of RNS60 in a pig model of acute myocardial infarction (AMI, heart attacks) at the 2013 American Heart Association Scientific Sessions in Dallas, Texas. As reported earlier this year at the American College of Cardiology meeting in San Francisco, RNS60 provided a […]
Revalesio Initiates Phase IIa Study of RNS60 in Multiple Sclerosis at University Hospital Zurich
TACOMA, Wash., Nov. 11, 2013 /PRNewswire/ — Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis (RRMS or […]
Mouse Model of Parkinson's Disease Shows Improved Brain Function, Motor Skills Due to Revalesio's RNS60
TACOMA, Wash., Oct. 16, 2013 /PRNewswire/ — A paper published in the Journal of Neuroimmune Pharmacology shows that Revalesio's novel therapeutic RNS60 significantly improved biochemical and behavioral (movement) outcomes in a mouse model of Parkinson's disease (PD). The research was conducted by the laboratory of Dr. Kalipada Pahan at Rush University Medical Center. The model used in […]
Revalesio Presents Data Showing RNS60 Alters Disease Progression in Animal Model of Alzheimer's Disease Through the PI3k-Akt Pathway
TACOMA, Wash., July 18, 2013 /PRNewswire/ — On Wednesday Revalesio Corporation presented new data at the Alzheimer's Association International Conference that identifies the specific cellular pathways by which Revalesio's lead investigational product, RNS60, impacts Alzheimer's Disease. This research, conducted in partnership with Rush University Medical Center, investigates a new category of therapeutics using Revalesio's novel […]
Revalesio's RNS60 Protects Myelin and Halts Multiple Sclerosis in Mice
TACOMA, Wash., Jan. 3, 2013 /PRNewswire/ — Results from a collaborative project between Revalesio and Dr. Kalipada Pahan at Rush University showed remarkable therapeutic activity of Revalesio's novel therapeutic RNS60 in a mouse model of multiple sclerosis (MS). In a study recently published in the journal PLOS ONE, RNS60 halted disease progression (as measured by progressive […]
